Drug repurposing in cancer

Autor: Linda Sleire, Inger Anne Netland, Per Øyvind Enger, Bente Sandvei Skeie, Hilde Elise Førde, Lina Leiss

Publikováno v: Pharmacological Research. 124:74-91

Cancer is a major health issue worldwide, and the global burden of cancer is expected to increase in the coming years. Whereas the limited success with current therapies has driven huge investments into drug development, the average number of FDA app

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb060af8e79221f560a528fb79c9dc6e
https://doi.org/10.1016/j.phrs.2017.07.013

Establishment of a Novel dsRed NOD/Scid Mouse Strain to Investigate the Host and Tumor Cell Compartments

Autor: Hege Karine Jacobsen, Ercan Mutlu, Hilde Elise Førde, Inger Anne Netland, Jian Wang, Paal-Henning Pedersen, Per Øyvind Enger, Linda Sleire, Donald Gullberg

Publikováno v: Cancer Investigation. 31:221-230

Here we describe a NOD/Scid mouse strain expressing the dsRed transgene. The strain is maintained by inbreeding of homozygous dsRed NOD/Scid siblings, and expresses red fluorescence from various organs. The model allows engraftment of human tumor tis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae25c4026d1394b5c686c7cfc3e749cc
https://doi.org/10.3109/07357907.2013.780075

Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma

Autor: Jesús Planagumà, Wouter R. van Furth, Jan Ingemann Heggdal, Joost J.C. Verhoeff, Per Øystein Sakariassen, Justyna Kmiecik, Agnete Svendsen, Inger Anne Netland, Martha Chekenya, Lars Prestegarden, Anneli Bohne Kjersem, Aurélie Poli, Rolf Bjerkvig, Andreas Waha, Morten Lund-Johansen, Nicolaas H. C. Brons, Karl Johan Tronstad, Per Øyvind Enger, Anja Torsvik, Heike Immervoll, Joerg Felsberg, Jan Brogger

Publikováno v: Acta Neuropathologica
Acta neuropathologica, 122(4), 495-510. Springer Verlag
Acta Neuropathologica, 122(4), 495-510. Springer Verlag

Glioblastoma (GBM) is a highly aggressive brain tumour, where patients respond poorly to radiotherapy and exhibit dismal survival outcomes. The mechanisms of radioresistance are not completely understood. However, cancer cells with an immature stem-l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a48515c655bd4ea2542ef369c3efdf8
https://doi.org/10.1007/s00401-011-0867-2

The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling

Autor: Martha Chekenya, Frode Selheim, Per Øystein Sakariassen, W. B. Stallcup, Inger Anne Netland, Camilla Krakstad, T. Sandal, Torgeir Flatmark, Rolf Bjerkvig, Agnete Svendsen, Per Øyvind Enger, Mouldi Sioud, Vidar Staalesen, Jian Wang, Per Eystein Lønning, Berit B. Tysnes

Publikováno v: Oncogene. 27(39)

Chemoresistance represents a major problem in the treatment of many malignancies. Overcoming this obstacle will require improved understanding of the mechanisms responsible for this phenomenon. The progenitor cell marker NG2/melanoma proteoglycan (MP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cc8c44e96dc80d711b0030111a06f64
https://pubmed.ncbi.nlm.nih.gov/18469852

Abstract LB-66: NVP-BEZ235 and bevacizumab as therapy for glioblastoma

Autor: Hilde Elise Førde, Dorota Goplen, Inger Anne Netland, Linda Sleire, B. S. Skeie, Per Øyvind Enger

Publikováno v: Cancer Research. 74:LB-66

Glioblastoma (GBM) is the most common and aggressive primary brain tumour. Its dismal prognosis despite multimodal treatment comprising surgery, radiotherapy and chemotherapy, calls for new therapeutic strategies. GBM is a highly vascularized cancer,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2f59b0a7018d09ffbadb16ebbb55f041
https://doi.org/10.1158/1538-7445.am2014-lb-66